(VIANEWS) – First Solar (FSLR), DexCom (DXCM), Upwork (UPWK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. First Solar (FSLR)
69.6% sales growth and 7.82% return on equity
First Solar, Inc. provides photovoltaic (PV) solar energy solutions in the United State, Japan, France, Canada, India, Australia, and internationally. The company designs, manufactures, and sells cadmium telluride solar modules that converts sunlight into electricity. It serves developers and operators of systems, utilities, independent power producers, commercial and industrial companies, and other system owners. The company was formerly known as First Solar Holdings, Inc. and changed its name to First Solar, Inc. in 2006. First Solar, Inc. was founded in 1999 and is headquartered in Tempe, Arizona.
Earnings Per Share
As for profitability, First Solar has a trailing twelve months EPS of $4.41.
PE Ratio
First Solar has a trailing twelve months price to earnings ratio of 36.38. Meaning, the purchaser of the share is investing $36.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.82%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 4757.1% and 517.5%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.4%, now sitting on 3.16B for the twelve trailing months.
Volume
Today’s last reported volume for First Solar is 1287120 which is 45.35% below its average volume of 2355460.
2. DexCom (DXCM)
28.1% sales growth and 18.42% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $0.91.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 138.97. Meaning, the purchaser of the share is investing $138.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.42%.
Previous days news about DexCom(DXCM)
- According to Zacks on Monday, 22 January, "This facility will likely help DexCom to support its supply of rtCGM sensors in Europe."
3. Upwork (UPWK)
14.8% sales growth and 4.44% return on equity
Upwork Inc., together with its subsidiaries, operates a work marketplace that connects businesses with various independent professionals and agencies in the United States, India, the Philippines, and internationally. The company's work marketplace provides access to talent with various skills across a range of categories, including sales and marketing, customer service, data science and analytics, design and creative, web, mobile, and software development. Its work marketplace also enables clients to streamline workflows, such as talent sourcing, outreach, and contracting. The company's work marketplace offers access to various functionalities for remote engagements with talent, including communication and collaboration, ability to receive talent invoices through their work marketplace, and payment protection. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Enterprise, and Upwork Payroll, as well as managed and internet escrow agency services. The company was formerly known as Elance-oDesk, Inc. and changed its name to Upwork Inc. in May 2015. Upwork Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, Upwork has a trailing twelve months EPS of $-0.19.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.44%.
Volume
Today’s last reported volume for Upwork is 269651 which is 87.91% below its average volume of 2232010.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Upwork’s EBITDA is 67.49.
Moving Average
Upwork’s worth is above its 50-day moving average of $14.37 and way higher than its 200-day moving average of $11.68.
Sales Growth
Upwork’s sales growth is 10.4% for the present quarter and 14.8% for the next.
4. Boston Scientific (BSX)
8.2% sales growth and 6.68% return on equity
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Per Share
As for profitability, Boston Scientific has a trailing twelve months EPS of $0.82.
PE Ratio
Boston Scientific has a trailing twelve months price to earnings ratio of 74.04. Meaning, the purchaser of the share is investing $74.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
Moving Average
Boston Scientific’s value is higher than its 50-day moving average of $56.13 and way higher than its 200-day moving average of $53.14.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Boston Scientific’s EBITDA is 88.46.
Previous days news about Boston Scientific(BSX)
- The zacks analyst blog highlights Microsoft, procter & gamble, astrazeneca, General Electric and Boston Scientific. According to Zacks on Monday, 22 January, "Stocks recently featured in the blog include: Microsoft Corp. (MSFT Quick QuoteMSFT – Free Report) , The Procter & Gamble Co. (PG Quick QuotePG – Free Report) , AstraZeneca PLC (AZN Quick QuoteAZN – Free Report) , General Electric Co. (GE Quick QuoteGE – Free Report) and Boston Scientific Corp. (BSX Quick QuoteBSX – Free Report) .", "Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period(You can read the full research report on AstaZeneca here >>>)Other noteworthy reports we are featuring today include General Electric Co. and Boston Scientific Corp."
